With Woodcock’s Retirement, US FDA Loses A Renaissance Woman

The FDA will go on without Janet Woodcock, but it will likely take multiple people to fill in the gaps given her breadth of institutional knowledge, interests and skill sets, former close colleagues told the Pink Sheet.

Janet Woodcock
• Source: Getty Images

Janet Woodcock will retire from the US Food and Drug Administration in early 2024 after more than 35 years at the agency she confirmed to the Pink Sheet on 16 November.

More from US FDA

More from Agency Leadership